Австралія - англійська - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate, quantity: 1.164 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime viatris is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used.. indications include:. severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns.. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections: for example, otitis media, mastoiditis.. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis.. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - ceftazidime pentahydrate, quantity: 2329.3 mg (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate; carbon dioxide - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the following. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns. respiratory tract. eg: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections. for example: otitis media, mastoiditis. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones. skin and soft tissue. for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal. for example: intra-abdominal abscesses, enterocolitis. bone and joint. for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - ceftazidime pentahydrate, quantity: 1165 mg (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate; carbon dioxide - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the following. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns. respiratory tract. eg: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections. for example: otitis media, mastoiditis. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones. skin and soft tissue. for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal. for example: intra-abdominal abscesses, enterocolitis. bone and joint. for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 2.328 g (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime juno is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example: otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 1.164 g (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime juno is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example: otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - riboflavine sodium phosphate, quantity: 5.67 mg; pyridoxine hydrochloride, quantity: 5.5 mg; cyanocobalamin, quantity: 6 microgram; nicotinamide, quantity: 46 mg; dl-alpha-tocopherol, quantity: 10.2 mg; ascorbic acid, quantity: 125 mg; retinol palmitate, quantity: 3500 iu; colecalciferol, quantity: 5.5 microgram; dexpanthenol, quantity: 16.15 mg; biotin, quantity: 69 microgram; cocarboxylase tetrahydrate, quantity: 5.8 mg (equivalent: thiamine, qty 3.51 mg); folic acid, quantity: 414 microgram - injection, powder for - excipient ingredients: glycine; glycocholic acid; hydrochloric acid; sodium hydroxide; lecithin - cernevit is indicated in adults and children over 11 years of age requiring parenteral multivitamin supplementation to correct or prevent vitamin deficiencies when oral administration is contraindicated, impossible or insufficient. the product does not contain vitamin k, which may be given separately if required.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefotaxime sodium, quantity: 2096.4 mg (equivalent: cefotaxime, qty 2000 mg) - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower); infections of the urinary tract; septicaemia (concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism); intra-abdominal infection; gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoea); ear, nose and throat infections; skin and skin structure infections; bone and joint infections; meningitis: cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or benzylpenicillin) for initial therapy in children (excluding neonates) pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infec

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - erythromycin lactobionate, quantity: 1.4882 g/g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin-link (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and s

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin sodium, quantity: 530.1 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 119.2 mg (equivalent: clavulanic acid, qty 100 mg) - injection, powder for - excipient ingredients: - curam is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained.,infections caused by amoxicillin susceptible organisms are amenable to curam treatment due to its amoxicillin content.,infections caused by beta-lactamase producing amoxicillin resistant organisms are also amenable to curam due to its clavulanic acid content.,susceptibility to curam will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.,curam is indicated for the short term treatment of serious bacterial infections such as:,? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms,? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia,? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections,? gastrointestinal infections e.g. intra-abdominal sepsis, peritonitis.,? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess,? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections.,? curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastrointestinal surgery.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin sodium, quantity: 1.06 g (equivalent: amoxicillin, qty 1 g); potassium clavulanate, quantity: 238.3 mg (equivalent: clavulanic acid, qty 200 mg) - injection, powder for - excipient ingredients: - curam is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained.,infections caused by amoxicillin susceptible organisms are amenable to curam treatment due to its amoxicillin content.,infections caused by beta-lactamase producing amoxicillin resistant organisms are also amenable to curam due to its clavulanic acid content.,susceptibility to curam will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.,curam is indicated for the short term treatment of serious bacterial infections such as:,? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms,? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia,? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, , female genital infections,? gastrointestinal infections: e.g. intra-abdominal sepsis, peritonitis.,? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess,? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections.,? curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastrointestinal surgery.